CIT 2014:冠脉分叉病变RESOLVE评分

2014-03-12 窦克非 医心网

研究背景冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策略对术后即刻

研究背景

冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策略对术后即刻和远期临床效果都有决定性作用,影响分叉病变介入策略选择的最主要因素是介入治疗过程中分支血管闭塞风险。目前对分支血管闭塞风险的评估尚无客观标准,介入术者只能依靠自身主观经验。

研究通过全面系统的筛选影响分支闭塞的危险因素,建立分支闭塞风险评分系统,全面评价多个危险因素共同作用下患者分支闭塞的风险大小,可为指导临床介入策略选择提供统一的客观标准。

研究设计

研究是一项大规模、单中心、回顾性研究,研究主要有以下特点。首先,研究涵盖的患者群广,入选患者时除采用选择性双支架的分叉病变患者排除外,其他所有累及重要分支的分叉病变患者均纳入其中。这样一项大规模、覆盖广的研究能够更好地为临床实践提供更完善、可靠的证据。其次,研究纳入的样本量大,本研究连续纳入了2012年1月至2012年7月在阜外医院行支架置入术的1537例分叉病变患者,共计1601例分叉病变,充足的样本量保障了本研究结论可靠性。再次,本研究系统的分析了可能影响分支闭塞的危险因素,如患者的临床情况、病史资料、冠状动脉造影特点和介入操作情况等,且创新性的发现并纳入了主支/分支直径比这一新变量。在全面分析既往分支闭塞危险因素的同时,提出了新的重要预测变量。最后,根据筛选出的分支闭塞危险因素,建立了RESOLVE分支闭塞风险评分系统。

RESOLVE评分系统的建立是基于患者的临床情况、病史资料、冠状动脉造影特点和介入操作情况等多方面的危险因素,综合评价多个危险因素共同作用下患者分支闭塞的风险大小,切实为临床决策提供客观依据。

研究结果

通过多因素回归分析,本研究最终筛选出包括主支/分支直径比等在内的6个危险因素,并据此建立了RESOLVE评分系统,用以评价分叉病变患者在介入治疗过程中分支闭塞的风险,进而指导介入策略选择。通过验证数据集检验,RESOLVE评分系统具有很好的区分度,能够准确地根据分支闭塞风险将分叉病变患者划分为高危、中危、低危患者。

RESOLVE研究结果将会在CIT2014会议上正式公布,让我们拭目以待。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738460, encodeId=ba4c1e38460c2, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Jan 25 09:09:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793269, encodeId=ccc31e932695e, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Fri Jan 30 04:09:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493265, encodeId=8b7d1493265e3, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557336, encodeId=da6d155e3368b, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738460, encodeId=ba4c1e38460c2, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Jan 25 09:09:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793269, encodeId=ccc31e932695e, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Fri Jan 30 04:09:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493265, encodeId=8b7d1493265e3, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557336, encodeId=da6d155e3368b, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738460, encodeId=ba4c1e38460c2, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Jan 25 09:09:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793269, encodeId=ccc31e932695e, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Fri Jan 30 04:09:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493265, encodeId=8b7d1493265e3, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557336, encodeId=da6d155e3368b, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
    2014-03-14 hongbochen
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738460, encodeId=ba4c1e38460c2, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Jan 25 09:09:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793269, encodeId=ccc31e932695e, content=<a href='/topic/show?id=e0e91535453' target=_blank style='color:#2F92EE;'>#RESOLVE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15354, encryptionId=e0e91535453, topicName=RESOLVE)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Fri Jan 30 04:09:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493265, encodeId=8b7d1493265e3, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7026, encryptionId=4223e0260a, topicName=ESO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f59021057, createdName=hongbochen, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557336, encodeId=da6d155e3368b, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Fri Mar 14 07:09:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]

相关资讯

CIT 2014:SEEDS研究两年结果

SEEDS研究两年结果:残余SYNTAX Score、双联抗血小板治疗时间对置入第二代药物洗脱支架患者长期预后的预测作用及影响。SEEDS研究为前瞻性多中心注册研究,于2010年启动,在全国45个中心共入选1900例冠状动脉置入第二代药物洗脱支架(2nd DES)的小血管、长病变及多支血管病变的患者。以研究第二代药物洗脱支架在中国人群中使用的安全性和有效性,并在该人群中分析残余SYNTAX Sco

CIT 2012:P值的意义在减少

 在第十届中国介入心脏病学大会(CIT)上,第四届临床研究专题研讨峰会吸引了大量与会者。   美国哥伦比亚大学医学中心介入血管治疗中心的Ajay J. Kirtane对P值的意义进行了讨论。他强调,P<0.05可以告诉我们观察到的治疗差异是有统计学显著意义的,但P<0.05并未告诉我们真实的治疗效益对于临床的重要程度及其作用大小。P值检测反对无效假设的证据强度,一方面,如果P<

CIT 2014:TAVR发展及中国早期经验概况

自2002年法国的Cribier医生成功完成全球第一例经导管主动脉瓣置换(TAVR)术以来,该技术经过10余年的发展,目前已成为外科手术风险高或不能进行外科手术的症状性重度主动脉瓣狭窄有效的替代治疗方案。与传统的外科换瓣手术相比,TAVR具有微创(不需要开胸和体外循环)、术后恢复快等优势。PARTNER随机对照研究显示,对于无法接受外科手术的重度主动脉瓣狭窄患者,TAVR优于单纯的主动脉瓣球囊扩张

高润霖:中国经皮心血管介入治疗发展

        3月16日,在第十届中国介入心脏病学大会(CIT)开幕式上,大会主席、阜外心血管病医院高润霖院士回顾了我国经皮介入心血管治疗的发展。   我国首例经皮冠状动脉腔内成形术(PTCA)是1985年郑笑莲教授在西京医院实施的,病例报告在1986年发表。1988年,我国首次报告了用激光进行冠状动脉成形术,当时仅有几个中心进行,并在2005年停止实施。冠状动脉溶栓加PTCA治疗急性心